Myelodysplastic Syndrome-Pipeline Review, H1 2015

Myelodysplastic Syndrome-Pipeline Review, H1 2015

  • Products Id :- GMDHC6685IDB
  • |
  • Pages: 611
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Myelodysplastic Syndrome-Pipeline Review, H1 2015


Global Markets Direct's, 'Myelodysplastic Syndrome-Pipeline Review, H1 2015', provides an overview of the Myelodysplastic Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Myelodysplastic Syndrome and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Myelodysplastic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Myelodysplastic Syndrome pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 11

Introduction 12

Global Markets Direct Report Coverage 12

Myelodysplastic Syndrome Overview 13

Therapeutics Development 14

Pipeline Products for Myelodysplastic Syndrome-Overview 14

Pipeline Products for Myelodysplastic Syndrome-Comparative Analysis 15

Myelodysplastic Syndrome-Therapeutics under Development by Companies 16

Myelodysplastic Syndrome-Therapeutics under Investigation by Universities/Institutes 23

Myelodysplastic Syndrome-Pipeline Products Glance 25

Late Stage Products 25

Clinical Stage Products 26

Early Stage Products 27

Myelodysplastic Syndrome-Products under Development by Companies 28

Myelodysplastic Syndrome-Products under Investigation by Universities/Institutes 36

Myelodysplastic Syndrome-Companies Involved in Therapeutics Development 37

4SC AG 37

AbbVie Inc. 38

Acceleron Pharma, Inc. 39

Actinium Pharmaceuticals, Inc. 40

Advancell 41

Agios Pharmaceuticals, Inc. 42

Altor BioScience Corporation 43

Amgen Inc. 44

Apogenix GmbH 45

Aptose Biosciences Inc. 46

Array BioPharma Inc. 47

Astex Pharmaceuticals, Inc. 48

Bio-Path Holdings, Inc. 49

BioLineRx, Ltd. 50

Boehringer Ingelheim GmbH 51

Boryung Pharmaceutical Co., Ltd. 52

Boston Biomedical, Inc. 53

Bristol-Myers Squibb Company 54

Celator Pharmaceuticals, Inc. 55

Celgene Corporation 56

Celldex Therapeutics, Inc. 57

Cellerant Therapeutics, Inc. 58

Celyad 59

Clevexel Pharma SAS 60

Concert Pharmaceuticals, Inc. 61

Constellation Pharmaceuticals, Inc. 62

Cornerstone Pharmaceuticals, Inc. 63

CTI BioPharma Corp. 64

Cyclacel Pharmaceuticals, Inc. 65

Daiichi Sankyo Company, Limited 66

Eisai Co., Ltd. 67

Eleos Inc. 68

Eli Lilly and Company 69

EpiZyme, Inc. 70

F. Hoffmann-La Roche Ltd. 71

Fujifilm Corporation 72

Gamida Cell Ltd. 73

GlaxoSmithKline Plc 74

Incyte Corporation 75

Juno Therapeutics Inc. 76

JW Pharmaceutical Corporation 77

Kainos Medicine, Inc. 78

KaloBios Pharmaceuticals, Inc. 79

Karyopharm Therapeutics, Inc. 80

Kiadis Pharma B.V. 81

Kyowa Hakko Kirin Co., Ltd. 82

Les Laboratoires Servier SAS 83

Lixte Biotechnology Holdings, Inc. 84

medac GmbH 85

MedImmune, LLC 86

MEI Pharma, Inc. 87

Merck & Co., Inc. 88

Merus B.V. 89

Millennium Pharmaceuticals, Inc. 90

Mirati Therapeutics Inc. 91

Mirna Therapeutics, Inc. 92

Novartis AG 93

Onconova Therapeutics, Inc. 94

Opsona Therapeutics Ltd. 95

OXiGENE, Inc. 96

Pfizer Inc. 97

Pharma Mar, S.A. 98

Rich Pharmaceuticals, Inc. 99

Stemline Therapeutics, Inc. 100

Sumitomo Dainippon Pharma Co., Ltd. 101

Sunesis Pharmaceuticals, Inc. 102

Syndax Pharmaceuticals, Inc. 103

Synta Pharmaceuticals Corp. 104

TetraLogic Pharmaceuticals 105

Teva Pharmaceutical Industries Limited 106

Threshold Pharmaceuticals, Inc. 107

Tragara Pharmaceuticals, Inc. 108

Myelodysplastic Syndrome-Therapeutics Assessment 109

Assessment by Monotherapy Products 109

Assessment by Combination Products 110

Assessment by Target 111

Assessment by Mechanism of Action 117

Assessment by Route of Administration 122

Assessment by Molecule Type 124

Drug Profiles 126

(cytarabine hydrochloride + daunorubicin hydrochloride)-Drug Profile 126

(decitabine + E-7727)-Drug Profile 128

4SC-202-Drug Profile 130

acadesine-Drug Profile 132

AG-120-Drug Profile 134

ALT-803-Drug Profile 136

Antibody to Target Cancer Stem Cell for Cancer-Drug Profile 138

APG-101-Drug Profile 139

APTO-253-Drug Profile 141

ATIR-101-Drug Profile 143

azacitidine-Drug Profile 145

BBMPI-03-Drug Profile 148

BI-836858-Drug Profile 149

binimetinib-Drug Profile 150

birinapant-Drug Profile 155

BL-8040-Drug Profile 158

BLI-1301-Drug Profile 160

bortezomib-Drug Profile 161

BP-100101-Drug Profile 167

BR-05001-Drug Profile 169

CC-90007-Drug Profile 170

CDX-1401-Drug Profile 173

Cell Therapy to Target CD174 for Oncology-Drug Profile 175

Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies-Drug Profile 176

Cell Therapy to Target WT1 for Cancer-Drug Profile 177

cenersen sodium-Drug Profile 178

CIGB-300-Drug Profile 180

CMCS-1-Drug Profile 182

CPI-0610-Drug Profile 184

CPI-613-Drug Profile 185

CSC-012-Drug Profile 187

CTP-221-Drug Profile 188

CVXL-0056-Drug Profile 189

CWP-291-Drug Profile 191

darbepoetin alfa (recombinant)-Drug Profile 193

dasatinib-Drug Profile 195

Dendritic Cell Therapy for Hematological Malignancies-Drug Profile 198

Dendritic Cell Therapy for Oncology-Drug Profile 199

Dendritic Cell Therapy to Target WT1 for Oncology-Drug Profile 200

Drug to Inhibit NR2F6 Protein for Leukemia-Drug Profile 201

DS-3032-Drug Profile 202

DSP-7888-Drug Profile 203

durvalumab-Drug Profile 204

E-6201-Drug Profile 207

eltrombopag olamine-Drug Profile 209

entinostat-Drug Profile 212

epacadostat-Drug Profile 216

EPZ-5676-Drug Profile 218

erismodegib-Drug Profile 220

everolimus-Drug Profile 223

evofosfamide-Drug Profile 229

FF-10501-Drug Profile 237

galunisertib-Drug Profile 238

ganetespib-Drug Profile 240

glasdegib-Drug Profile 244

guadecitabine-Drug Profile 246

HDM-201-Drug Profile 249

ilorasertib-Drug Profile 250

indisulam-Drug Profile 252

Iomab-B-Drug Profile 253

ixazomib citrate-Drug Profile 255

JTCR-016-Drug Profile 259

KB-004-Drug Profile 260

KHK-2823-Drug Profile 262

KM-101-Drug Profile 263

LB-100-Drug Profile 264

lenalidomide-Drug Profile 266

lirilumab-Drug Profile 270

lurbinectedin-Drug Profile 272

luspatercept-Drug Profile 275

MCLA-117-Drug Profile 276

midostaurin-Drug Profile 277

mocetinostat-Drug Profile 279

Monoclonal Antibodies to Target CD16 and CD33 for Oncology-Drug Profile 282

Monoclonal Antibody Conjugate 2 to Target CD45 for Cancer-Drug Profile 283

Monoclonal Antibody Conjugate to Inhibit Protein S100-A9 for MDS-Drug Profile 284

Monoclonal Antibody Conjugate to Target CD45 for Oncology-Drug Profile 285

MRX-102-Drug Profile 286

MRX-34-Drug Profile 288

napabucasin-Drug Profile 290

NiCord-Drug Profile 293

omacetaxine mepesuccinate-Drug Profile 294

ONC-201-Drug Profile 297

OPN-305-Drug Profile 299

OXi-4503-Drug Profile 301

pacritinib-Drug Profile 303

pembrolizumab-Drug Profile 305

pevonedistat hydrochloride-Drug Profile 312

pexmetinib-Drug Profile 314

PIM-447-Drug Profile 315

pracinostat-Drug Profile 316

quizartinib dihydrochloride-Drug Profile 318

rigosertib sodium-Drug Profile 321

RP-323-Drug Profile 325

ruxolitinib phosphate-Drug Profile 326

S-055746-Drug Profile 331

sapacitabine-Drug Profile 332

selinexor-Drug Profile 334

SL-401-Drug Profile 339

Small Molecule to Inhibit KDM1A for AML, MDS and Sickle Cell Disease-Drug Profile 341

Small Molecules for Myelodysplastic Syndrome-Drug Profile 342

sotatercept-Drug Profile 343

StemEx-Drug Profile 346

temozolomide-Drug Profile 347

TEN-010-Drug Profile 349

TG-02-Drug Profile 350

tosedostat-Drug Profile 353

trametinib dimethyl sulfoxide-Drug Profile 355

treosulfan-Drug Profile 358

ulixertinib-Drug Profile 360

Vaccine for Oncology-Drug Profile 361

Vaccine to Target Wilms Tumor Protein for Oncology-Drug Profile 362

Vaccine to Target WT1 for Oncology-Drug Profile 363

vismodegib-Drug Profile 364

volasertib-Drug Profile 367

vorinostat-Drug Profile 370

vosaroxin-Drug Profile 374

WT-4869-Drug Profile 376

Myelodysplastic Syndrome-Recent Pipeline Updates 377

Myelodysplastic Syndrome-Dormant Projects 587

Myelodysplastic Syndrome-Discontinued Products 591

Myelodysplastic Syndrome-Product Development Milestones 593

Featured News & Press Releases 593

Appendix 602

Methodology 602

Coverage 602

Secondary Research 602

Primary Research 602

Expert Panel Validation 602

Contact Us 602

Disclaimer 603

List of Tables

Number of Products under Development for Myelodysplastic Syndrome, H1 2015 22

Number of Products under Development for Myelodysplastic Syndrome-Comparative Analysis, H1 2015 23

Number of Products under Development by Companies, H1 2015 25

Number of Products under Development by Companies, H1 2015 (Contd..1) 26

Number of Products under Development by Companies, H1 2015 (Contd..2) 27

Number of Products under Development by Companies, H1 2015 (Contd..3) 28

Number of Products under Development by Companies, H1 2015 (Contd..4) 29

Number of Products under Development by Companies, H1 2015 (Contd..5) 30

Number of Products under Investigation by Universities/Institutes, H1 2015 32

Comparative Analysis by Late Stage Development, H1 2015 33

Comparative Analysis by Clinical Stage Development, H1 2015 34

Comparative Analysis by Early Stage Development, H1 2015 35

Products under Development by Companies, H1 2015 36

Products under Development by Companies, H1 2015 (Contd..1) 37

Products under Development by Companies, H1 2015 (Contd..2) 38

Products under Development by Companies, H1 2015 (Contd..3) 39

Products under Development by Companies, H1 2015 (Contd..4) 40

Products under Development by Companies, H1 2015 (Contd..5) 41

Products under Development by Companies, H1 2015 (Contd..6) 42

Products under Development by Companies, H1 2015 (Contd..7) 43

Products under Investigation by Universities/Institutes, H1 2015 44

Myelodysplastic Syndrome-Pipeline by 4SC AG, H1 2015 45

Myelodysplastic Syndrome-Pipeline by AbbVie Inc., H1 2015 46

Myelodysplastic Syndrome-Pipeline by Acceleron Pharma, Inc., H1 2015 47

Myelodysplastic Syndrome-Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 48

Myelodysplastic Syndrome-Pipeline by Advancell, H1 2015 49

Myelodysplastic Syndrome-Pipeline by Agios Pharmaceuticals, Inc., H1 2015 50

Myelodysplastic Syndrome-Pipeline by Altor BioScience Corporation, H1 2015 51

Myelodysplastic Syndrome-Pipeline by Amgen Inc., H1 2015 52

Myelodysplastic Syndrome-Pipeline by Apogenix GmbH, H1 2015 53

Myelodysplastic Syndrome-Pipeline by Aptose Biosciences Inc., H1 2015 54

Myelodysplastic Syndrome-Pipeline by Array BioPharma Inc., H1 2015 55

Myelodysplastic Syndrome-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 56

Myelodysplastic Syndrome-Pipeline by Bio-Path Holdings, Inc., H1 2015 57

Myelodysplastic Syndrome-Pipeline by BioLineRx, Ltd., H1 2015 58

Myelodysplastic Syndrome-Pipeline by Boehringer Ingelheim GmbH, H1 2015 59

Myelodysplastic Syndrome-Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2015 60

Myelodysplastic Syndrome-Pipeline by Boston Biomedical, Inc., H1 2015 61

Myelodysplastic Syndrome-Pipeline by Bristol-Myers Squibb Company, H1 2015 62

Myelodysplastic Syndrome-Pipeline by Celator Pharmaceuticals, Inc., H1 2015 63

Myelodysplastic Syndrome-Pipeline by Celgene Corporation, H1 2015 64

Myelodysplastic Syndrome-Pipeline by Celldex Therapeutics, Inc., H1 2015 65

Myelodysplastic Syndrome-Pipeline by Cellerant Therapeutics, Inc., H1 2015 66

Myelodysplastic Syndrome-Pipeline by Celyad, H1 2015 67

Myelodysplastic Syndrome-Pipeline by Clevexel Pharma SAS, H1 2015 68

Myelodysplastic Syndrome-Pipeline by Concert Pharmaceuticals, Inc., H1 2015 69

Myelodysplastic Syndrome-Pipeline by Constellation Pharmaceuticals, Inc., H1 2015 70

Myelodysplastic Syndrome-Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 71

Myelodysplastic Syndrome-Pipeline by CTI BioPharma Corp., H1 2015 72

Myelodysplastic Syndrome-Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015 73

Myelodysplastic Syndrome-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 74

Myelodysplastic Syndrome-Pipeline by Eisai Co., Ltd., H1 2015 75

Myelodysplastic Syndrome-Pipeline by Eleos Inc., H1 2015 76

Myelodysplastic Syndrome-Pipeline by Eli Lilly and Company, H1 2015 77

Myelodysplastic Syndrome-Pipeline by EpiZyme, Inc., H1 2015 78

Myelodysplastic Syndrome-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 79

Myelodysplastic Syndrome-Pipeline by Fujifilm Corporation, H1 2015 80

Myelodysplastic Syndrome-Pipeline by Gamida Cell Ltd., H1 2015 81

Myelodysplastic Syndrome-Pipeline by GlaxoSmithKline Plc, H1 2015 82

Myelodysplastic Syndrome-Pipeline by Incyte Corporation, H1 2015 83

Myelodysplastic Syndrome-Pipeline by Juno Therapeutics Inc., H1 2015 84

Myelodysplastic Syndrome-Pipeline by JW Pharmaceutical Corporation, H1 2015 85

Myelodysplastic Syndrome-Pipeline by Kainos Medicine, Inc., H1 2015 86

Myelodysplastic Syndrome-Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 87

Myelodysplastic Syndrome-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 88

Myelodysplastic Syndrome-Pipeline by Kiadis Pharma B.V., H1 2015 89

Myelodysplastic Syndrome-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 90

Myelodysplastic Syndrome-Pipeline by Les Laboratoires Servier SAS, H1 2015 91

Myelodysplastic Syndrome-Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015 92

Myelodysplastic Syndrome-Pipeline by medac GmbH, H1 2015 93

Myelodysplastic Syndrome-Pipeline by MedImmune, LLC, H1 2015 94

Myelodysplastic Syndrome-Pipeline by MEI Pharma, Inc., H1 2015 95

Myelodysplastic Syndrome-Pipeline by Merck & Co., Inc., H1 2015 96

Myelodysplastic Syndrome-Pipeline by Merus B.V., H1 2015 97

Myelodysplastic Syndrome-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 98

Myelodysplastic Syndrome-Pipeline by Mirati Therapeutics Inc., H1 2015 99

Myelodysplastic Syndrome-Pipeline by Mirna Therapeutics, Inc., H1 2015 100

Myelodysplastic Syndrome-Pipeline by Novartis AG, H1 2015 101

Myelodysplastic Syndrome-Pipeline by Onconova Therapeutics, Inc., H1 2015 102

Myelodysplastic Syndrome-Pipeline by Opsona Therapeutics Ltd., H1 2015 103

Myelodysplastic Syndrome-Pipeline by OXiGENE, Inc., H1 2015 104

Myelodysplastic Syndrome-Pipeline by Pfizer Inc., H1 2015 105

Myelodysplastic Syndrome-Pipeline by Pharma Mar, S.A., H1 2015 106

Myelodysplastic Syndrome-Pipeline by Rich Pharmaceuticals, Inc., H1 2015 107

Myelodysplastic Syndrome-Pipeline by Stemline Therapeutics, Inc., H1 2015 108

Myelodysplastic Syndrome-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 109

Myelodysplastic Syndrome-Pipeline by Sunesis Pharmaceuticals, Inc., H1 2015 110

Myelodysplastic Syndrome-Pipeline by Syndax Pharmaceuticals, Inc., H1 2015 111

Myelodysplastic Syndrome-Pipeline by Synta Pharmaceuticals Corp., H1 2015 112

Myelodysplastic Syndrome-Pipeline by TetraLogic Pharmaceuticals, H1 2015 113

Myelodysplastic Syndrome-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 114

Myelodysplastic Syndrome-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 115

Myelodysplastic Syndrome-Pipeline by Tragara Pharmaceuticals, Inc., H1 2015 116

Assessment by Monotherapy Products, H1 2015 117

Assessment by Combination Products, H1 2015 118

Number of Products by Stage and Target, H1 2015 120

Number of Products by Stage and Mechanism of Action, H1 2015 126

Number of Products by Stage and Route of Administration, H1 2015 131

Number of Products by Stage and Molecule Type, H1 2015 133

Myelodysplastic Syndrome Therapeutics-Recent Pipeline Updates, H1 2015 385

Myelodysplastic Syndrome-Dormant Projects, H1 2015 595

Myelodysplastic Syndrome-Dormant Projects (Contd..1), H1 2015 596

Myelodysplastic Syndrome-Dormant Projects (Contd..2), H1 2015 597

Myelodysplastic Syndrome-Dormant Projects (Contd..3), H1 2015 598

Myelodysplastic Syndrome-Discontinued Products, H1 2015 599

Myelodysplastic Syndrome-Discontinued Products (Contd..1), H1 2015 600

List of Figures

Number of Products under Development for Myelodysplastic Syndrome, H1 2015 22

Number of Products under Development for Myelodysplastic Syndrome-Comparative Analysis, H1 2015 23

Number of Products under Development by Companies, H1 2015 24

Number of Products under Investigation by Universities/Institutes, H1 2015 31

Comparative Analysis by Clinical Stage Development, H1 2015 34

Comparative Analysis by Early Stage Products, H1 2015 35

Assessment by Monotherapy Products, H1 2015 117

Assessment by Combination Products, H1 2015 118

Number of Products by Top 10 Targets, H1 2015 119

Number of Products by Stage and Top 10 Targets, H1 2015 119

Number of Products by Top 10 Mechanism of Actions, H1 2015 125

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 125

Number of Products by Top 10 Routes of Administration, H1 2015 130

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 130

Number of Products by Top 10 Molecule Types, H1 2015 132

Number of Products by Stage and Top 10 Molecule Types, H1 2015 132

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]


AbbVie Inc.

Acceleron Pharma, Inc.

Actinium Pharmaceuticals, Inc.


Agios Pharmaceuticals, Inc.

Altor BioScience Corporation

Amgen Inc.

Apogenix GmbH

Aptose Biosciences Inc.

Array BioPharma Inc.

Astex Pharmaceuticals, Inc.

Bio-Path Holdings, Inc.

BioLineRx, Ltd.

Boehringer Ingelheim GmbH

Boryung Pharmaceutical Co., Ltd.

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Celator Pharmaceuticals, Inc.

Celgene Corporation

Celldex Therapeutics, Inc.

Cellerant Therapeutics, Inc.


Clevexel Pharma SAS

Concert Pharmaceuticals, Inc.

Constellation Pharmaceuticals, Inc.

Cornerstone Pharmaceuticals, Inc.

CTI BioPharma Corp.

Cyclacel Pharmaceuticals, Inc.

Daiichi Sankyo Company, Limited

Eisai Co., Ltd.

Eleos Inc.

Eli Lilly and Company

EpiZyme, Inc.

F. Hoffmann-La Roche Ltd.

Fujifilm Corporation

Gamida Cell Ltd.

GlaxoSmithKline Plc

Incyte Corporation

Juno Therapeutics Inc.

JW Pharmaceutical Corporation

Kainos Medicine, Inc.

KaloBios Pharmaceuticals, Inc.

Karyopharm Therapeutics, Inc.

Kiadis Pharma B.V.

Kyowa Hakko Kirin Co., Ltd.

Les Laboratoires Servier SAS

Lixte Biotechnology Holdings, Inc.

medac GmbH

MedImmune, LLC

MEI Pharma, Inc.

Merck & Co., Inc.

Merus B.V.

Millennium Pharmaceuticals, Inc.

Mirati Therapeutics Inc.

Mirna Therapeutics, Inc.

Novartis AG

Onconova Therapeutics, Inc.

Opsona Therapeutics Ltd.


Pfizer Inc.

Pharma Mar, S.A.

Rich Pharmaceuticals, Inc.

Stemline Therapeutics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Sunesis Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc.

Synta Pharmaceuticals Corp.

TetraLogic Pharmaceuticals

Teva Pharmaceutical Industries Limited

Threshold Pharmaceuticals, Inc.

Tragara Pharmaceuticals, Inc.

Myelodysplastic Syndrome Therapeutic Products under Development, Key Players in Myelodysplastic Syndrome Therapeutics, Myelodysplastic Syndrome Pipeline Overview, Myelodysplastic Syndrome Pipeline, Myelodysplastic Syndrome Pipeline Assessment

select a license

Single User License
USD 2000 INR 134900
Site License
USD 4000 INR 269800
Corporate User License
USD 6000 INR 404700



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]